Literature DB >> 27987741

A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies.

Lalaji V Rathod1, Rakhee Kapadia1, Krutika K Sawant2.   

Abstract

The present investigation was carried out to demonstrate with the help of in vitro and in vivo studies that nanoparticles impregnated ocular inserts effectively delivers significant concentration of drug to the posterior segment of eye after topical administration for treatment of glaucoma. Drug loaded Nanoparticles and their ocular insert have been reported to reduce side effects of orally administered Acetazolamide. Eudragit NPs were prepared by the solvent diffusion nanoprecipitation technique. The prepared NPs were evaluated for various parameters such as particle size, zeta potential, % entrapment efficiency, % drug loading, DSC, FTIR, TEM and stability studies. Ocular inserts of NPs were prepared by solvent casting method. The prepared ocular inserts were evaluated for thickness, content uniformity, folding endurance, disintegration time, morphology and stability study. The NPs and ocular inserts were evaluated for in-vitro drug diffusion study, ex-vivo trans-corneal permeability study, in-vivo ocular tolerability and intra ocular pressure (IOP) reduction study. The optimized batch was stable for a period of 3months in lyophilized form. The optimized formulations had size range of 367nm±8nm, zeta potential around +7mV±1.3mV and 51.61%±3.84% entrapment efficiency with 19%±1.40% drug loading. The ex-vivo trans-corneal study showed higher cumulative corneal permeation, flux across corneal tissue (2.460±0.028μg/ml) and apparent corneal permeability (3.926×10-6cm2/s &amp; 3.863×10-6cm2/s) from drug loaded Eudragit NPs and Ocular inserts as compared to drug solution (0.671±0.020μg/ml &amp; 3.166×10-6cm2/s). In-vivo study showed the Eudragit NPs and ocular insert produced significant (P<0.001) lowering in intra ocular pressure compared with the solution of free drug after 3h of topical ocular administration. Plain Eudragit NPs caused no inflammation and/or discomfort in rabbit eyes and neither affected the intra ocular pressure establishing their safety and non irritancy.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetazolamide; Eudragit NPs; Glaucoma treatment; Nanoprecipitation; Ocular drug delivery; Ocular inserts

Mesh:

Substances:

Year:  2016        PMID: 27987741     DOI: 10.1016/j.msec.2016.10.017

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  7 in total

Review 1.  Principles of pharmacology in the eye.

Authors:  Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood
Journal:  Br J Pharmacol       Date:  2017-10-10       Impact factor: 8.739

2.  Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels.

Authors:  Russell Macoon; Anuj Chauhan
Journal:  Eur J Pharm Sci       Date:  2020-11-01       Impact factor: 4.384

3.  Tailored nanostructured platforms for boosting transcorneal permeation: Box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization.

Authors:  Ibrahim Elsayed; Sinar Sayed
Journal:  Int J Nanomedicine       Date:  2017-10-30

4.  Novel cubosome based system for ocular delivery of acetazolamide.

Authors:  Hoda E Teba; Islam A Khalil; Heba M El Sorogy
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

5.  Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: Preparation, in vitro characterization, ex vivo and in vivo assessments.

Authors:  Sadek Ahmed; Maha M Amin; Sarah Mohamed El-Korany; Sinar Sayed
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Eudragit® L100/Polyvinyl Alcohol Nanoparticles Impregnated Mucoadhesive Films as Ocular Inserts for Controlled Delivery of Erythromycin: Development, Characterization and In Vivo Evaluation.

Authors:  Shahla Mirzaeei; Shiva Taghe; Raid G Alany; Ali Nokhodchi
Journal:  Biomedicines       Date:  2022-08-08

Review 7.  Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.

Authors:  Marcelo Luís Occhiutto; Raul C Maranhão; Vital Paulino Costa; Anastasios G Konstas
Journal:  Adv Ther       Date:  2019-12-10       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.